Page 263 - IJB-9-4

International Journal of Bioprinting Applications of 3D printing in aging

49. Mussatto A, Groarke R, O’Neill A, et al., 2021, Influences 61. Mattson MP, et al., 1992, beta-Amyloid peptides destabilize
of powder morphology and spreading parameters on the calcium homeostasis and render human cortical neurons
powder bed topography uniformity in powder bed fusion vulnerable to excitotoxicity. J Neurosci, 12:376–389.
metal additive manufacturing. Addit Manuf, 38:101807.
https://doi.org/10.1523/jneurosci.12-02-00376.1992
https://doi.org/10.1016/j.addma.2020.101807
62. Citron M, Westaway D, Xia W, et al., 1997, Mutant
50. Awad A, Fina F, Goyanes A, et al., 2021, Advances in powder presenilins of Alzheimer’s disease increase production of
bed fusion 3D printing in drug delivery and healthcare. Adv 42-residue amyloid beta-protein in both transfected cells
Drug Deliv Rev, 174:406–424. and transgenic mice. Nat Med, 3:67–72.
https://doi.org/10.1016/j.addr.2021.04.025 https://doi.org/10.1038/nm0197-67
51. Chen W, Yang J, Kong H, et al., 2021, Fatigue behaviour 63. Bloom GS, 2014, Amyloid-β and tau: The trigger and bullet in
and biocompatibility of additively manufactured bioactive Alzheimer disease pathogenesis. JAMA Neurol, 71:505–508.
tantalum graded lattice structures for load-bearing https://doi.org/10.1001/jamaneurol.2013.5847
orthopaedic applications. Mater Sci Eng C Mater Biol Appl,
130:112461. 64. Selkoe DJ, 2001, Alzheimer’s disease: Genes, proteins, and
therapy. Physiol Rev, 81:741–766.
https://doi.org/10.1016/j.msec.2021.112461
https://doi.org/10.1152/physrev.2001.81.2.741
52. Zhao D, Liang H, Han C, et al., 2021, 3D printing of a
titanium-tantalum gyroid scaffold with superb elastic 65. Tolosa E, Garrido A, Scholz SW, et al., 2021, Challenges in the
admissible strain, bioactivity and in-situ bone regeneration diagnosis of Parkinson’s disease. Lancet Neurol, 20:385–397.
capability. Addit Manuf, 47:102223. https://doi.org/10.1016/s1474-4422(21)00030-2
https://doi.org/10.1016/j.addma.2021.102223 66. Choudhury SP, Bano S, Sen S, et al., 2022, Altered neural
53. Asefy Z, Hoseinnejhad S, Ceferov Z, 2021, Nanoparticles cell junctions and ion-channels leading to disrupted neuron
approaches in neurodegenerative diseases diagnosis and communication in Parkinson’s disease. NPJ Parkinsons Dis, 8:66.
treatment. Neurol Sci, 42:2653–2660. https://doi.org/10.1038/s41531-022-00324-9
https://doi.org/10.1007/s10072-021-05234-x 67. de Lau LM, Breteler MM, 2006, Epidemiology of Parkinson’s
54. Alzheimer’s A, et al., 2019, 2019 Alzheimer’s disease facts disease. Lancet Neurol, 5:525–535.
and figures. Alzheimers Dement, 15:321–387. https://doi.org/10.1016/s1474-4422(06)70471-9
https://doi.org/10.1016/j.jalz.2019.01.010 68. Al-Chalabi A, Hardiman O, 2013, The epidemiology of
55. Poewe W, Seppi K, Tanner C, et al., 2017, Parkinson disease. ALS: A conspiracy of genes, environment and time. Nat Rev
Nat Rev Dis Prim, 3:17013 . Neurol, 9:617–628.
https://doi.org/10.1038/nrneurol.2013.203
https://doi.org/10.1038/nrdp.2017.13
69. Yun Y, Ha Y, 2020, CRISPR/Cas9-mediated gene correction
56. Nussbaum RL, Ellis CE, 2003, Genomic medicine:
Alzheimer’s disease and Parkinson’s disease. N Engl J Med, to understand ALS. Int J Mol Sci, 21.
348:1356–1364. https://doi.org/10.3390/ijms21113801
https://doi.org/10.1056/NEJM2003ra020003 70. Yang X, Ji Y, Wang W, et al., Amyotrophic lateral sclerosis:
Molecular mechanisms, biomarkers, and therapeutic
57. Mehta P, Antao V, Sanchez M, et al., 2014, Prevalence of strategies. Antioxidants (Basel), 10(7):1012.
amyotrophic lateral sclerosis (ALS) in the United States. Ann
Neurol, 76, S64–S64. https://doi.org/10.3390/antiox10071012
58. Hsiao YH, Chang CH, Gean PW, 2018, Impact of social 71. Selim OA, Lakhani S, Midha S, et al., 2022, Three-
relationships on Alzheimer’s memory impairment: dimensional engineered peripheral nerve: Toward a new era
Mechanistic studies. J Biomed Sci, 25:3. of patient-specific nerve repair solutions. Tissue Eng Part B
Rev, 28:295–335.
https://doi.org/10.1186/s12929-018-0404-x
https://doi.org/10.1089/ten.TEB.2020.0355
59. Ross CA, Poirier MA, 2004, Protein aggregation and
neurodegenerative disease. Nat Med, 10(Suppl):S10–S17. 72. Zhuang P, Sun AX, An J, et al., 2018, 3D neural tissue models:
From spheroids to bioprinting. Biomaterials, 154:113–133.
https://doi.org/10.1038/nm1066
https://doi.org/10.1016/j.biomaterials.2017.10.002
60. Mattson MP, Cheng B, Davis D, et al., 2019, Apolipoprotein
E and Alzheimer disease: Pathobiology and targeting 73. Shamir ER, Ewald AJ, 2014, Three-dimensional organotypic
strategies. Nat Rev Neurol, 15:501–518. culture: experimental models of mammalian biology and
disease. Nat Rev Mol Cell Biol, 15:647–664.
https://doi.org/10.1038/s41582-019-0228-7
https://doi.org/10.1038/nrm3873
Volume 9 Issue 4 (2023) 255 https://doi.org/10.18063/ijb.732